Protego Biopharma closed a $130 million oversubscribed Series B to advance PROT-001, an oral small-molecule stabilizer for AL amyloidosis, into a pivotal trial planned for H2 2026. The company describes PROT-001 as a kinetic stabilizer that binds lambda light chains to prevent amyloid formation and restore proteostasis. Protego said proceeds will fund the pivotal study and broader development of its pharmacological-chaperone platform across misfolding diseases. CEO Brent Warner positioned the approach as complementary to plasma-cell–directed therapies and said the company plans tandem strategies with standard-of-care regimens.